[{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AVZO-021","moa":"CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Avenzo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Allorion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"AVZO-021","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ Avenzo Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Avenzo Therapeutics \/ Avenzo Therapeutics"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"AVZO-021","moa":"||CDK2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Avenzo Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series A Financing","leadProduct":"AVZO-021","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenzo Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ New Enterprise Associates","highestDevelopmentStatusID":"7","companyTruncated":"Avenzo Therapeutics \/ New Enterprise Associates"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Allorion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"AVZO-023","moa":"CDK4","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ Avenzo Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Avenzo Therapeutics \/ Avenzo Therapeutics"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Duality Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"DB-1418","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avenzo Therapeutics","amount2":1.2,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":1.2,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ Avenzo Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Avenzo Therapeutics \/ Avenzo Therapeutics"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"AVZO-1418","moa":"EGFR\/HER3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Avenzo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"AVZO-1418","moa":"EGFR|HER3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Avenzo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Avenzo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"AVZO-103","moa":"Nectin4\/TROP2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Avenzo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"VelaVigo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ Avenzo Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Avenzo Therapeutics \/ Avenzo Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Avenzo Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : AVZO-103, a potential best-in-class Nectin4/TROP2 bispecific antibody-drug conjugate. It is being evaluated for the treatment of advanced solid tumors.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          September 02, 2025

                          Lead Product(s) : AVZO-103

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : AVZO-1418 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          June 26, 2025

                          Lead Product(s) : AVZO-1418

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Fulvestrant is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 31, 2025

                          Lead Product(s) : Fulvestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : AVZO-1418, a potential best-in-class, novel EGFR/HER3 bispecific antibody-drug conjugate. It is being evaluated for the treatment of advanced solid tumors.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          May 22, 2025

                          Lead Product(s) : AVZO-1418

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Under the licensing agreement, Avenzo has exercised its exclusive option for global (excluding Greater China) development, manufacturing, and commercialization rights for AVZO-023.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          May 21, 2025

                          Lead Product(s) : AVZO-023

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Recipient : Allorion Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          06

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Under the licensing agreement, Venzo will develop, manufacture and commercialize AVZO-1418 (DB-1418), a potential best-in-class bispecific ADC for treating neoplasms.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : $50.0 million

                          January 07, 2025

                          Lead Product(s) : DB-1418

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Recipient : Duality Biologics

                          Deal Size : $1,200.0 million

                          Deal Type : Licensing Agreement

                          blank

                          07

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Avenzo gains an exclusive option to an exclusive license to develop, manufacture and commercialize a potential first-in-class Nectin4/TROP2 bispecific ADC globally (excluding Greater China).

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          November 18, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Recipient : VelaVigo

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          08

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : The collaboration aims to evaluate AVZO-021, a best-in-class CDK2 inhibitor, in combination with Gilead’s Trodelvy (sacituzumab govitecan), for patients with HR-positive, HER2-negative breast cancer.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          September 03, 2024

                          Lead Product(s) : AVZO-021,Sacituzumab Govitecan

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Gilead Sciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          09

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Proceeds will advance Avenzo’s ARTS-021, a selective CDK2 inhibitor in a Phase 1 study for HR+/HER2- metastatic breast cancer and other advanced solid tumors.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          March 26, 2024

                          Lead Product(s) : AVZO-021,Fulvestrant,Letrozole

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : New Enterprise Associates

                          Deal Size : $150.0 million

                          Deal Type : Series A Financing

                          blank

                          10

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Under the agreement, Avenzo will develop and commercialize AVZO-021 (formerly ARTS-021), a potentially best-in-class cyclin-dependent kinase 2 selective inhibitor globally, excluding Greater China.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          January 04, 2024

                          Lead Product(s) : AVZO-021,Fulvestrant,Palbociclib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Allorion Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank